IMR Press / RCM / Volume 4 / Issue S1 / pii/1561439351340-1011628489

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
A Review of Contemporary Prevention Strategies for Radiocontrast Nephropathy: A Focus on Fenoldopam and N-Acetylcysteine
Show Less
1 UCLA School of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
Rev. Cardiovasc. Med. 2003, 4(S1), 15–20;
Published: 20 January 2003
The mechanism most likely responsible for the development of radiocontrast nephropathy (RCN) is contrast-induced renal tubular ischemia. At this time, intravenous hydration remains the mainstay for preventing RCN. The antihypertensive agent fenoldopam has been shown in a canine model, as well as in small, retrospective, prospective, and randomized human evaluations, to be effective for preventing RCN. In addition, studies have reported the ability of the free radical scavenger N-acetylcysteine (NAC) to prevent RCN. The clinical trial data for NAC, however, are not consistent regarding this effect, which, if present, appears to be modest and perhaps restricted to lower-risk clinical scenarios.
Radiocontrast nephropathy
Intravenous hydration
Back to top